Related Experiment Video
Updated: Jul 15, 2026
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis
E T H Ek1, C R Dass, K G Contreras
1Department of Orthopaedics, University of Melbourne, St Vincent's Hospital, Melbourne, Victoria, Australia.
Abstract:
Despite significant improvements, the current management of primary osteosarcoma is still limited by the development of metastatic disease, which occurs in approximately 30% of patients despite aggressive multiagent chemotherapy and tumor-ablative surgery. Therefore, there is a need for the development of novel agents to improve the outcome of these patients. Pigment epithelium-derived factor (PEDF) has been shown to be one of the most potent inhibitors of angiogenesis, and more recently has demonstrated a functional role in tumor growth, invasion and metastasis. In this study we report, for the first time, the multitargeted role of PEDF in the inhibition of growth, angiogenesis and metastasis of two orthotopic models of osteosarcoma (rat UMR 106-01 and human SaOS-2). Through stable plasmid-mediated gene transfer of full-length human PEDF, we show that PEDF overexpression significantly reduced tumor cell proliferation (P<0.05) and Matrigel invasion (UMR(PEDF), P<0.001; SaOS(PEDF), P<0.05) and increased adhesion to collagen type-1 (P<0.01), in vitro. In vivo, PEDF overexpression dramatically suppressed orthotopic osteosarcoma growth (P<0.05) and the development of spontaneous pulmonary metastases (UMR(PEDF), P<0.05; SaOS(PEDF), P<0.001). Furthermore, PEDF-overexpressing tumors exhibited reduced intratumoral angiogenesis, evidenced by a significant decrease in microvessel density (P<0.05). Therefore, together these results suggest that PEDF may be a new and promising approach for the treatment of osteosarcoma.
Insights
Pigment epithelium-derived factor (PEDF) shows promise in treating osteosarcoma by inhibiting tumor growth, invasion, and metastasis. This study demonstrates PEDF
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Osteosarcoma treatment faces limitations due to metastatic disease development in a significant patient subset.
- Novel therapeutic agents are crucial to improve outcomes for osteosarcoma patients.
- Pigment epithelium-derived factor (PEDF) is recognized for its anti-angiogenic properties and role in tumor progression.
Purpose of the Study:
- To investigate the multitargeted therapeutic potential of Pigment epithelium-derived factor (PEDF) in osteosarcoma.
- To evaluate PEDF's efficacy in inhibiting osteosarcoma growth, angiogenesis, and metastasis in preclinical models.
Main Methods:
- Stable plasmid-mediated gene transfer of full-length human PEDF into osteosarcoma cell lines (rat UMR 106-01 and human SaOS-2).
- In vitro assessment of tumor cell proliferation, invasion, and adhesion to collagen type-1.
- In vivo evaluation of orthotopic osteosarcoma growth and spontaneous pulmonary metastasis development in preclinical models.
Main Results:
- PEDF overexpression significantly reduced osteosarcoma cell proliferation and Matrigel invasion in vitro.
- PEDF overexpression increased osteosarcoma cell adhesion to collagen type-1.
- In vivo, PEDF overexpression dramatically suppressed tumor growth, pulmonary metastasis, and intratumoral angiogenesis, evidenced by reduced microvessel density.
Conclusions:
- Pigment epithelium-derived factor (PEDF) demonstrates significant inhibitory effects on osteosarcoma growth, angiogenesis, and metastasis.
- PEDF exhibits a multitargeted role in controlling key aspects of osteosarcoma progression.
- PEDF represents a promising novel therapeutic candidate for osteosarcoma treatment.
Related Concept Videos
01:24Regulation of Angiogenesis and Blood Supply
02:38Mitogens and the Cell Cycle